Drug recall · January 15, 2014
FIBRICOR recall
Why: Labeling: Incorrect instructions; an error in section 5.11 of the patient insert that results in incorrect medical advice. Specifically, the labeling should read "If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated." The labeling for the recalled lots
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
FIBRICOR (fenofibric acid) Tablets, 105 mg, a) 30 count bottle (NDC 13310-102-07), b) 90 count bottle (NDC 13310-102-90), Manufactured for AR SCIENTIFIC, INC, Philadelphia, PA 19124 USA
- Lots / codes
Lots 6504705, 6504706 exp. 05/14
- Company
- Mutual Pharmaceutical Company, Inc., Philadelphia, PA
- Distribution
- Nationwide and Puerto Rico.
- Initiated
- February 27, 2013 · Voluntary: Firm initiated
- Classified
- January 6, 2014
- Reported
- January 15, 2014
- Ended
- April 1, 2014
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.